Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Telik
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Primary or de novo MDS
Low or intermediate-1 MDS
ECOG performance status 0 or 1
Documented significant anemia with or without neutropenia and/or thrombocytopenia
Adequate kidney and liver function
Patients must have discontinued hematopoietic growth factors at least 3 weeks prior to study entry
You may not be if
Prior allogenic bone marrow transplant for MDS
History of MDS IPSS score greater than 1.0
Pregnant or lactating women
Any severe concurrent disease, infection, or comorbidity that, in the judgement of the investigator, would make the patient inappropriate for study entry
Oral steroids e.g. prednisone \>10 mg per day
History of active hepatitis B or C
Known history of HIV
Clareo Health | Phase 2 Study Comparing Two Dose Schedules of Telintra™ in Myelodysplastic Syndrome (MDS)
